Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Microbot Medical Inc. (NASDAQ: MBOT), a commercial stage medical device company focused on the LIBERTY Endovascular Robotic System. Through these filings, investors can review how the company reports material events, financing transactions, intellectual property developments and key commercialization steps for its endovascular robotics platform.
Microbot Medical uses current reports on Form 8-K to disclose significant milestones, including FDA 510(k) clearance for the LIBERTY System, the start of its limited market release in the U.S., and the first hospital adoption of LIBERTY for patient care at Emory University Hospital. Other 8-K filings describe partnerships with a U.S.-based third-party logistics provider to support commercialization, as well as the company’s exhibition of LIBERTY at major medical meetings.
Several 8-K filings also detail capital markets activity, such as the exercise of outstanding preferred investment options, issuance of new short-term preferred investment options and related gross proceeds. In these documents, Microbot Medical outlines intended uses of funds, including continued development, commercialization and regulatory activities for the LIBERTY Robotic System, potential acquisitions of complementary assets or products, expansion of applications derived from its IP portfolio, and working capital and general corporate purposes.
Additional filings address intellectual property events, such as the granting of the company’s first patent in Japan covering core LIBERTY System technology, and certain compensation decisions for executives and non-management directors. On Stock Titan, these filings are updated as they are made available through EDGAR, and AI-powered summaries can help explain the context and key points of each document, from material event disclosures to financing terms and governance changes related to MBOT.
Microbot Medical Inc. (MBOT) filed Amendment No. 1 to its shelf registration statement, stating it is being made solely to add Rule 473(b) language for automatic effectiveness 20 days after filing and to update a cross-reference in the Exhibit Index. The amendment does not modify any prospectus, and a preliminary prospectus has been omitted.
The filing notes the registration will become effective in accordance with Section 8(a), and the company may amend to delay or change effectiveness if the SEC resumes full operation beforehand. Disclosed offering-related expenses total $27,000.00, including an SEC registration fee of $6,592.60, legal fees of $5,000.00, accounting fees of $12,000.00, and miscellaneous expenses of $3,407.40.
Microbot Medical (MBOT) reported it will exhibit its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, FL on October 17–19, 2025. This marks the first medical meeting where the company will commercially exhibit the LIBERTY® System following its FDA 510(k) clearance.
The company also announced it has recently completed the hiring and on‑boarding of its commercial leadership team. The disclosure was furnished under Regulation FD.
Microbot Medical announced a partnership with a U.S.-based third-party logistics provider to support commercialization of its FDA-cleared LIBERTY Endovascular Robotic System. The company plans a limited market release in the fourth quarter of 2025, followed by a broader launch in April 2026 aligned with the Society of Interventional Radiology conference.
The disclosure was furnished under Regulation FD and as an Other Event, with a related press release included as Exhibit 99.1.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 prospectus registering up to 14,688,572 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options, including 13,989,115 Series J options at an exercise price of $4.50 per share. This prospectus does not cover the issuance of the underlying shares to the holders and the company is not selling any shares.
Microbot will not receive proceeds from stockholder resales. If all 14,688,572 options are exercised for cash, the company may receive up to approximately $64.8 million in gross proceeds; certain options permit cashless exercise. Shares outstanding were 67,158,044 as of October 10, 2025. Listed methods permit brokerage transactions, block trades, privately negotiated sales, and short sales after the registration statement is declared effective.
MBOT trades on Nasdaq; the last reported closing price on October 10, 2025 was $2.92.
Microbot Medical Inc. (MBOT) filed a preliminary S-3 registering up to 900,153 shares of common stock for resale by selling stockholders. The shares may be issued upon exercise of outstanding preferred investment options held by those stockholders. The company is not selling shares in this offering and will not receive proceeds from any resales.
Microbot may receive up to approximately $2.1 million in gross proceeds only if all registered options are exercised for cash; some options allow cashless exercise. The plan of distribution permits multiple methods, including short sales after the registration statement is declared effective. Examples include Noam Rubenstein 283,548 and Michael Vasinkevich 577,223 from the selling stockholder table. Shares outstanding were 67,158,044 as of October 10, 2025. MBOT last closed at $2.92 on October 10, 2025.
Microbot Medical Inc. reports that on October 6, 2025, a holder exercised 1,324,488 existing series H preferred investment options for 1,324,488 shares of common stock at an exercise price of $2.10 per share. Under a previously disclosed inducement letter agreement, the holder also received 1,324,488 new series J preferred investment options.
This transaction represents the third and final closing under that inducement arrangement, which was required to occur on or before October 15, 2025. Microbot also issued 66,224 preferred investment options to H.C. Wainwright & Co., LLC under a May 29, 2024 engagement letter, as amended.
The new preferred investment options and the Wainwright preferred investment options, and the shares underlying them, were issued as unregistered securities in reliance on Section 4(a)(2) of the Securities Act and may be resold only pursuant to registration or an applicable exemption. Shares issuable upon exercise of the existing options are already registered under a post-effective amendment to a Form S-1 registration statement. The company also noted it issued a press release on October 7, 2025 announcing this third closing.
Microbot Medical Inc. reported several recent equity transactions involving preferred investment options and common stock. On September 29, 2025, a holder exercised 600,000 series H preferred investment options for 600,000 shares of common stock at an exercise price of $2.10 per share and, under a prior inducement letter, received 600,000 new series J preferred investment options. The company also issued 30,000 preferred investment options to H.C. Wainwright & Co., LLC under an existing engagement letter, all in unregistered transactions relying on Section 4(a)(2) of the Securities Act.
Separately, on September 23, 2025, Microbot issued 374,167 shares of common stock upon exercise of an equal number of preferred investment options at exercise prices between $1.875 and $2.6625, generating approximately $896,000 in gross proceeds before fees. The resale of shares issuable from the previously issued series H options is covered by an effective registration statement, while the new options and their underlying shares remain unregistered and subject to resale restrictions.
Microbot Medical Inc. reported that the Japanese Patent Office has granted the company its first patent in Japan covering the core LIBERTY® System technology.
The patent relates to a compact robotic device used to drive and control the movement of at least one long surgical tool, supporting the company’s robotic surgery platform. The company also furnished a press release with the same information as an exhibit to the report.
Microbot Medical Inc. filed a Form D reporting a completed Regulation D private offering under Rule 506(b). The issuer raised aggregate proceeds of $25,244,903, of which $25,244,903 has been sold and $0 remains. The filing states the total offering amount reflects the aggregate exercise price of inducement preferred investment options and placement-agent preferred investment options. The placement agent received cash fees totaling $2,095,542 and was also granted 1,342,694 preferred investment options exercisable for common stock at prices ranging from $1.875 to $2.6625. The offering was a new notice with a first sale date of 2025-09-16, claimed a minimum investment of $0, and was not part of a business combination. The Form D was signed by CFO Rachel Vaknin on 2025-09-29.
Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.
The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.